Datamonitor’s OTC Pharmaceuticals: Global Industry Guide is an essential resource for top-level data and analysis covering the OTC Pharmaceuticals industry. It includes detailed data on market size and segmentation, textual analysis of the key trends and competitive landscape, and profiles of the leading companies. This incisive report provides expert analysis on a global, regional and country basis.
Scope of the Report
* Contains an executive summary and data on value, volume and segmentation
* Provides textual analysis of the industry’s prospects, competitive landscape and profiles of the leading companies
* Incorporates in-depth five forces competitive environment analysis and scorecards
* Covers the Global, European and Asia-Pacific markets as well as individual chapters on 5 major markets (France, Germany, Japan, the UK and the US).
* Includes a five-year forecast of the industry
Highlights
The global OTC pharmaceuticals market grew by 3.9% in 2009 to reach a value of $110.7 billion.
In 2014, the global OTC pharmaceuticals market is forecast to have a value of $131.6 billion, an increase of 18.9% since 2009.
Cough and cold preparations is the largest segment of the global OTC pharmaceuticals market, accounting for 17.6% of the market’s total value.
Europe accounts for 38% of the global OTC pharmaceuticals market value.
Johnson & Johnson is the leading player in the global OTC pharmaceuticals market, generating a 12.8% share of the market’s value.
The global over-the-counter (OTC) pharmaceutical market is highly fragmented, with the top three players holding 23% of the total market b
Why you should buy this report
* Spot future trends and developments
* Inform your business decisions
* Add weight to presentations and marketing materials
* Save time carrying out entry-level research
Market Definition
The OTC pharmaceuticals market consists of the retail sale of traditional medicines, cough and cold preparations (tablets, mixtures, lozenges, topical remedies, inhalers), vitamins and minerals (multi-vitamins, single minerals, single vitamins, tonics, cod liver oil), indigestion preparations (tablets, powders, mixtures), analgesics (Paracetamol, Ibuprofen, Aspirinand other analgesics), and medicated skin products (anti-bacteria’s, acne treatments, anti-fungal, disinfectants and other), topical OTC medicines (anesthetic products, anti-itch products, antibiotic creams/gels), plasters & bandages (adhesive bandages/plasters, first aid tape, gauze pads/rolled gauze, liquid bandages and other tape or bandage), first aid kits and other (anti-smoking aids, rectal medications, eye/ear drops, sleeping aids, and motion sickness).
EXECUTIVE SUMMARY 2
INTRODUCTION 22
What Is This Report About? 22
Who Is The Target Reader? 22
Market Definition 22
GLOBAL OTC PHARMACEUTICALS 23
Market Overview 23
Market Value 24
Market Segmentation I 25
Market segmentation II 26
Market Share 27
Five Forces Analysis 28
Market Distribution 36
Market Forecasts 37
OTC PHARMACEUTICALS IN ASIAPACIFIC 39
Market Overview 39
Market Value 40
Market Segmentation I 41
Market segmentation II 42
Market Share 43
Five Forces Analysis 44
Market Distribution 52
Market Forecasts 53
OTC PHARMACEUTICALS IN EUROPE 55
Market Overview 55
Market Value 56
Market Segmentation I 57
Market segmentation II 58
Market Share 59
Five Forces Analysis 60
Market Distribution 68
Market Forecasts 69
OTC PHARMACEUTICALS IN BELGIUM 71
Market Overview 71
Market Value 72
Market Segmentation I 73
Market segmentation II 74
Market Share 75
Five Forces Analysis 76
Market Distribution 85
Market Forecasts 86
Macroeconomic Indicators 88
OTC PHARMACEUTICALS IN CANADA 90
Market Overview 90
Market Value 91
Market Segmentation I 92
Market segmentation II 93
Market Share 94
Five Forces Analysis 95
Market Distribution 103
Market Forecasts 104
Macroeconomic Indicators 105
OTC PHARMACEUTICALS IN CHINA 107
Market Overview 107
Market Value 108
Market Segmentation I 109
Market segmentation II 110
Market Share 111
Five Forces Analysis 112
Market Distribution 120
Market Forecasts 121
Macroeconomic Indicators 122
OTC PHARMACEUTICALS IN FRANCE 124
Market Overview 124
Market Value 125
Market Segmentation I 126
Market segmentation II 127
Market Share 128
Five Forces Analysis 129
Market Distribution 137
Market Forecasts 138
Macroeconomic Indicators 139
OTC PHARMACEUTICALS IN GERMANY 141
Market Overview 141
Market Value 142
Market Segmentation I 143
Market segmentation II 144
Market Share 145
Five Forces Analysis 146
Market Distribution 153
Market Forecasts 154
Macroeconomic Indicators 155
OTC PHARMACEUTICALS IN ITALY 157
Market Overview 157
Market Value 158
Market Segmentation I 159
Market segmentation II 160
Market Share 161
Five Forces Analysis 162
Market Distribution 170
Market Forecasts 171
Macroeconomic Indicators 173
OTC PHARMACEUTICALS IN JAPAN 175
Market Overview 175
Market Value 176
Market Segmentation I 177
Market segmentation II 178
Market Share 179
Five Forces Analysis 180
Market Distribution 187
Market Forecasts 188
Macroeconomic Indicators 189
OTC PHARMACEUTICALS IN THE NETHERLANDS 191
Market Overview 191
Market Value 192
Market Segmentation I 193
Market segmentation II 194
Market Share 195
Five Forces Analysis 196
Market Distribution 205
Market Forecasts 206
Macroeconomic Indicators 208
OTC PHARMACEUTICALS IN SPAIN 210
Market Overview 210
Market Value 211
Market Segmentation I 212
Market segmentation II 213
Market Share 214
Five Forces Analysis 215
Market Distribution 223
Market Forecasts 224
Macroeconomic Indicators 225
OTC PHARMACEUTICALS IN THE UNITED KINGDOM 227
Market Overview 227
Market Value 228
Market Segmentation I 229
Market segmentation II 230
Market Share 231
Five Forces Analysis 232
Market Distribution 240
Market Forecasts 241
Macroeconomic Indicators 242
OTC PHARMACEUTICALS IN THE UNITED STATES 244
Market Overview 244
Market Value 245
Market Segmentation I 246
Market segmentation II 247
Market Share 248
Five Forces Analysis 249
Market Distribution 257
Market Forecasts 258
Macroeconomic Indicators 259
COMPANY PROFILES 261
Johnson & Johnson 261
GlaxoSmithKline Plc 268
Bayer AG 275
APPENDIX 282
Data Research Methodology 282
About Datamonitor 283
Disclaimer 283
LIST OF TABLES
Table 1: Global OTC pharmaceuticals market value: $ million, 2005–09 24
Table 2: Global OTC pharmaceuticals market segmentation I:% share, by value, 2009 25
Table 3: Global OTC pharmaceuticals Market segmentation II: % share, by value, 2009 26
Table 4: Global OTC pharmaceuticals market share: % share, by value, 2009 27
Table 5: Global OTC pharmaceuticals market distribution: % share, by value, 2009 36
Table 6: Global OTC pharmaceuticals market value forecast: $ million, 2009–14 37
Table 7: Asia-Pacific OTC pharmaceuticals market value: $ million, 2005–09 40
Table 8: Asia-Pacific OTC pharmaceuticals market segmentation I:% share, by value, 2009 41
Table 9: Asia-Pacific OTC pharmaceuticals Market segmentation II: % share, by value, 2009 42
Table 10: Asia-Pacific OTC pharmaceuticals market share: % share, by value, 2009 43
Table 11: Asia-Pacific OTC pharmaceuticals market distribution: % share, by value, 2009 52
Table 12: Asia-Pacific OTC pharmaceuticals market value forecast: $ million, 2009–14 53
Table 13: Europe OTC pharmaceuticals market value: $ million, 2005–09 56
Table 14: Europe OTC pharmaceuticals market segmentation I:% share, by value, 2009 57
Table 15: Europe OTC pharmaceuticals Market segmentation II: % share, by value, 2009 58
Table 16: Europe OTC pharmaceuticals market share: % share, by value, 2009 59
Table 17: Europe OTC pharmaceuticals market distribution: % share, by value, 2009 68
Table 18: Europe OTC pharmaceuticals market value forecast: $ million, 2009–14 69
Table 19: Belgium OTC pharmaceuticals market value: $ million, 2005–09 72
Table 20: Belgium OTC pharmaceuticals market segmentation I:% share, by value, 2009 73
Table 21: Belgium OTC pharmaceuticals Market segmentation II: % share, by value, 2009 74
Table 22: Belgium OTC pharmaceuticals market share: % share, by value, 2009 75
Table 23: Belgium OTC pharmaceuticals market distribution: % share, by value, 2009 85
Table 24: Belgium OTC pharmaceuticals market value forecast: $ million, 2009–14 86
Table 25: Belgium size of population (million), 2005–09 88
Table 26: Belgium gdp (constant 2000 prices, $ billion), 2005–09 88
Table 27: Belgium gdp (current prices, $ billion), 2005–09 88
Table 28: Belgium inflation, 2005–09 89
Table 29: Belgium consumer price index (absolute), 2005–09 89
Table 30: Belgium exchange rate, 2005–09 89
Table 31: Canada OTC pharmaceuticals market value: $ million, 2005–09 91
Table 32: Canada OTC pharmaceuticals market segmentation I:% share, by value, 2009 92
Table 33: Canada OTC pharmaceuticals Market segmentation II: % share, by value, 2009 93
Table 34: Canada OTC pharmaceuticals market share: % share, by value, 2009 94
Table 35: Canada OTC pharmaceuticals market distribution: % share, by value, 2009 103
Table 36: Canada OTC pharmaceuticals market value forecast: $ million, 2009–14 104
Table 37: Canada size of population (million), 2005–09 105
Table 38: Canada gdp (constant 2000 prices, $ billion), 2005–09 105
Table 39: Canada gdp (current prices, $ billion), 2005–09 105
Table 40: Canada inflation, 2005–09 106
Table 41: Canada consumer price index (absolute), 2005–09 106
Table 42: Canada exchange rate, 2005–09 106
Table 43: China OTC pharmaceuticals market value: $ million, 2005–09 108
Table 44: China OTC pharmaceuticals market segmentation I:% share, by value, 2009 109
Table 45: China OTC pharmaceuticals Market segmentation II: % share, by value, 2009 110
Table 46: China OTC pharmaceuticals market share: % share, by value, 2009 111
Table 47: China OTC pharmaceuticals market distribution: % share, by value, 2009 120
Table 48: China OTC pharmaceuticals market value forecast: $ million, 2009–14 121
Table 49: China size of population (million), 2005–09 122
Table 50: China gdp (constant 2000 prices, $ billion), 2005–09 122
Table 51: China gdp (current prices, $ billion), 2005–09 122
Table 52: China inflation, 2005–09 123
Table 53: China consumer price index (absolute), 2005–09 123
Table 54: China exchange rate, 2005–09 123
Table 55: France OTC pharmaceuticals market value: $ million, 2005–09 125
Table 56: France OTC pharmaceuticals market segmentation I:% share, by value, 2009 126
Table 57: France OTC pharmaceuticals Market segmentation II: % share, by value, 2009 127
Table 58: France OTC pharmaceuticals market share: % share, by value, 2009 128
Table 59: France OTC pharmaceuticals market distribution: % share, by value, 2009 137
Table 60: France OTC pharmaceuticals market value forecast: $ million, 2009–14 138
Table 61: France size of population (million), 2005–09 139
Table 62: France gdp (constant 2000 prices, $ billion), 2005–09 139
Table 63: France gdp (current prices, $ billion), 2005–09 139
Table 64: France inflation, 2005–09 140
Table 65: France consumer price index (absolute), 2005–09 140
Table 66: France exchange rate, 2005–09 140
Table 67: Germany OTC pharmaceuticals market value: $ million, 2005–09 142
Table 68: Germany OTC pharmaceuticals market segmentation I:% share, by value, 2009 143
Table 69: Germany OTC pharmaceuticals Market segmentation II: % share, by value, 2009 144
Table 70: Germany OTC pharmaceuticals market share: % share, by value, 2009 145
Table 71: Germany OTC pharmaceuticals market distribution: % share, by value, 2009 153
Table 72: Germany OTC pharmaceuticals market value forecast: $ million, 2009–14 154
Table 73: Germany size of population (million), 2005–09 155
Table 74: Germany gdp (constant 2000 prices, $ billion), 2005–09 155
Table 75: Germany gdp (current prices, $ billion), 2005–09 155
Table 76: Germany inflation, 2005–09 156
Table 77: Germany consumer price index (absolute), 2005–09 156
Table 78: Germany exchange rate, 2005–09 156
Table 79: Italy OTC pharmaceuticals market value: $ million, 2005–09 158
Table 80: Italy OTC pharmaceuticals market segmentation I:% share, by value, 2009 159
Table 81: Italy OTC pharmaceuticals Market segmentation II: % share, by value, 2009 160
Table 82: Italy OTC pharmaceuticals market share: % share, by value, 2009 161
Table 83: Italy OTC pharmaceuticals market distribution: % share, by value, 2009 170
Table 84: Italy OTC pharmaceuticals market value forecast: $ million, 2009–14 171
Table 85: Italy size of population (million), 2005–09 173
Table 86: Italy gdp (constant 2000 prices, $ billion), 2005–09 173
Table 87: Italy gdp (current prices, $ billion), 2005–09 173
Table 88: Italy inflation, 2005–09 174
Table 89: Italy consumer price index (absolute), 2005–09 174
Table 90: Italy exchange rate, 2005–09 174
Table 91: Japan OTC pharmaceuticals market value: $ million, 2005–09 176
Table 92: Japan OTC pharmaceuticals market segmentation I:% share, by value, 2009 177
Table 93: Japan OTC pharmaceuticals Market segmentation II: % share, by value, 2009 178
Table 94: Japan OTC pharmaceuticals market share: % share, by value, 2009 179
Table 95: Japan OTC pharmaceuticals market distribution: % share, by value, 2009 187
Table 96: Japan OTC pharmaceuticals market value forecast: $ million, 2009–14 188
Table 97: Japan size of population (million), 2005–09 189
Table 98: Japan gdp (constant 2000 prices, $ billion), 2005–09 189
Table 99: Japan gdp (current prices, $ billion), 2005–09 189
Table 100: Japan inflation, 2005–09 190
Table 101: Japan consumer price index (absolute), 2005–09 190
Table 102: Japan exchange rate, 2005–09 190
Table 103: Netherlands OTC pharmaceuticals market value: $ million, 2005–09 192
Table 104: Netherlands OTC pharmaceuticals market segmentation I:% share, by value, 2009 193
Table 105: Netherlands OTC pharmaceuticals Market segmentation II: % share, by value, 2009 194
Table 106: Netherlands OTC pharmaceuticals market share: % share, by value, 2009 195
Table 107: Netherlands OTC pharmaceuticals market distribution: % share, by value, 2009 205
Table 108: Netherlands OTC pharmaceuticals market value forecast: $ million, 2009–14 206
Table 109: Netherlands size of population (million), 2005–09 208
Table 110: Netherlands gdp (constant 2000 prices, $ billion), 2005–09 208
Table 111: Netherlands gdp (current prices, $ billion), 2005–09 208
Table 112: Netherlands inflation, 2005–09 209
Table 113: Netherlands consumer price index (absolute), 2005–09 209
Table 114: Netherlands exchange rate, 2005–09 209
Table 115: Spain OTC pharmaceuticals market value: $ million, 2005–09 211
Table 116: Spain OTC pharmaceuticals market segmentation I:% share, by value, 2009 212
Table 117: Spain OTC pharmaceuticals Market segmentation II: % share, by value, 2009 213
Table 118: Spain OTC pharmaceuticals market share: % share, by value, 2009 214
Table 119: Spain OTC pharmaceuticals market distribution: % share, by value, 2009 223
Table 120: Spain OTC pharmaceuticals market value forecast: $ million, 2009–14 224
Table 121: Spain size of population (million), 2005–09 225
Table 122: Spain gdp (constant 2000 prices, $ billion), 2005–09 225
Table 123: Spain gdp (current prices, $ billion), 2005–09 225
Table 124: Spain inflation, 2005–09 226
Table 125: Spain consumer price index (absolute), 2005–09 226
Table 126: Spain exchange rate, 2005–09 226
Table 127: United Kingdom OTC pharmaceuticals market value: $ million, 2005–09 228
Table 128: United Kingdom OTC pharmaceuticals market segmentation I:% share, by value, 2009 229
Table 129: United Kingdom OTC pharmaceuticals Market segmentation II: % share, by value, 2009 230
Table 130: United Kingdom OTC pharmaceuticals market share: % share, by value, 2009 231
Table 131: United Kingdom OTC pharmaceuticals market distribution: % share, by value, 2009 240
Table 132: United Kingdom OTC pharmaceuticals market value forecast: $ million, 2009–14 241
Table 133: United Kingdom size of population (million), 2005–09 242
Table 134: United Kingdom gdp (constant 2000 prices, $ billion), 2005–09 242
Table 135: United Kingdom gdp (current prices, $ billion), 2005–09 242
Table 136: United Kingdom inflation, 2005–09 243
Table 137: United Kingdom consumer price index (absolute), 2005–09 243
Table 138: United Kingdom exchange rate, 2005–09 243
Table 139: United States OTC pharmaceuticals market value: $ million, 2005–09 245
Table 140: United States OTC pharmaceuticals market segmentation I:% share, by value, 2009 246
Table 141: United States OTC pharmaceuticals Market segmentation II: % share, by value, 2009 247
Table 142: United States OTC pharmaceuticals market share: % share, by value, 2009 248
Table 143: United States OTC pharmaceuticals market distribution: % share, by value, 2009 257
Table 144: United States OTC pharmaceuticals market value forecast: $ million, 2009–14 258
Table 145: United States size of population (million), 2005–09 259
Table 146: United States gdp (constant 2000 prices, $ billion), 2005–09 259
Table 147: United States gdp (current prices, $ billion), 2005–09 259
Table 148: United States inflation, 2005–09 260
Table 149: United States consumer price index (absolute), 2005–09 260
Table 150: United States exchange rate, 2005–09 260
Table 151: Johnson & Johnson: key facts 261
Table 152: Johnson & Johnson: key financials ($) 265
Table 153: Johnson & Johnson: key financial ratios 265
Table 154: GlaxoSmithKline Plc: key facts 268
Table 155: GlaxoSmithKline Plc: key financials ($) 271
Table 156: GlaxoSmithKline Plc: key financials (£) 272
Table 157: GlaxoSmithKline Plc: key financial ratios 272
Table 158: Bayer AG: key facts 275
Table 159: Bayer AG: key financials ($) 279
Table 160: Bayer AG: key financials (€) 279
Table 161: Bayer AG: key financial ratios 280
Other selected research from the 'Business Development' category:
Partnering Agreements with Boehringer Ingelheim 2010
This report provides all the information you require to better understand Boehringer Ingelheim Labs and its partnering interests and activities over the past five years. Learn More
Partneringdesk Watson Pharmaceuticals, Inc. and Company Deals Briefing
Other selected research from the 'Publication Series' category:
Emerging Markets Series: The Pharmaceutical Market of Saudi Arabia
OTC Pharmaceuticals: Global Industry Guide
Other selected research from the 'Companies' category:
Partnering Agreements with Big Pharma
This premier report... Learn More
Daiichi Sankyo Co., Ltd: PharmaVitae Model 2009